Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Artiva Biotherapeutics, Inc. ( (ARTV) ) has shared an update.
On February 18, 2026, Artiva Biotherapeutics appointed veteran pharmaceutical executive Elaine Sorg as a Class I director, with her term running until the company’s 2028 annual shareholder meeting. The decision followed a recommendation from the Nominating and Corporate Governance Committee, and the company noted there were no related-party arrangements or disclosable transactions tied to her selection.
Sorg brings more than 35 years of senior leadership experience at major pharmaceutical groups including AbbVie and Eli Lilly, where she last served as Senior Vice President and President of AbbVie’s U.S. commercial operations until January 2024. Her appointment strengthens Artiva’s board with deep U.S. commercial and global healthcare expertise and is accompanied by standard non-employee director compensation, including an annual cash retainer and time-vested stock options that align her incentives with long-term shareholder interests.
The most recent analyst rating on (ARTV) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.
Spark’s Take on ARTV Stock
According to Spark, TipRanks’ AI Analyst, ARTV is a Neutral.
The score is held back primarily by collapsing revenue, persistent large losses, and escalating cash burn that increase financing risk. This is partially offset by strong recent technical trend/momentum and a positive clinical-trial update, while valuation remains constrained by negative earnings and no dividend signal.
To see Spark’s full report on ARTV stock, click here.
More about Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. operates in the biotherapeutics industry, focusing on developing and commercializing innovative medicines, particularly in areas such as immunology, oncology, neuroscience and related therapeutic fields. The company targets serious diseases with advanced biologic treatments and participates in a competitive global biopharmaceutical market.
Average Trading Volume: 1,036,257
Technical Sentiment Signal: Buy
Current Market Cap: $100.9M
For a thorough assessment of ARTV stock, go to TipRanks’ Stock Analysis page.